Non-Hodgkin Lymphoma Therapeutics Market - By Type (B-cell [Diffuse Large, Follicular, Mantle Cell], T-cell [Peripheral, Cutaneous, Anaplastic Large Cell], Therapy Type (Chemotherapy, Radiation, Targeted Therapy), Gender – Global Forecast (2024 – 2032)

Non-Hodgkin Lymphoma Therapeutics Market - By Type (B-cell [Diffuse Large, Follicular, Mantle Cell], T-cell [Peripheral, Cutaneous, Anaplastic Large Cell], Therapy Type (Chemotherapy, Radiation, Targeted Therapy), Gender – Global Forecast (2024 – 2032)

Non-Hodgkin Lymphoma Therapeutics Market Size

Non-Hodgkin Lymphoma Therapeutics Market size was valued at USD 9.5 billion in 2023 and is estimated to grow at 7.4% CAGR from 2024 to 2032. The market has experienced significant growth due to the increasing prevalence of Non-Hodgkin lymphoma worldwide.

To get key market trends

  Download Free Sample

For instance, according to a study published by the American Society of Hematology in November 2022, approximately 779,000 new cases of Non-Hodgkin lymphoma are projected by 2040, marking a 43% increase from 2020. This growing burden of Non-Hodgkin lymphoma is anticipated to drive market growth. Additionally, the market is driven by a growing demand for cost-effective and accessible therapeutic solutions. Healthcare systems worldwide face the challenge of providing efficient oncology treatment within budget limitations. As a result, the escalating demand for treatments that offer both clinical efficacy and financial viability for patients drives further expansion in the market growth.

Non-Hodgkin lymphoma therapeutics refers to the range of medical treatments designed to manage and treat Non-Hodgkin lymphoma, a diverse group of blood cancers that originate in the lymphatic system. These therapies cover various approaches including chemotherapy, targeted therapy, radiation therapy, and stem cell transplantation.
 

What are the growth opportunities in this market?

 Download Free Sample

Non-Hodgkin Lymphoma Therapeutics Market Trends

The expanded funding and intensified R&D activities facilitated the advancement of innovative therapies, spanning targeted treatments, immunotherapies, and chemotherapy protocols, thereby driving market growth.

• For instance, the Leukemia & Lymphoma Society (LLS) has awarded a USD 5 million grant to researchers at Washington University School of Medicine in St. Louis to advance research in creating novel immunotherapies for various blood-based cancers. This funding supports 2-3 projects, including research on T-cell Non-Hodgkin lymphoma treatment, aiming to broaden research efforts for potential blood cancer therapeutics, including lymphoma.

Thus, ongoing research for the development of combined therapies and innovative approaches to enhance treatment effectiveness coupled with growing partnerships among pharmaceutical, academic, and research institutions are few factors fostering the expansion of market.

Non-Hodgkin Lymphoma Therapeutics Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

Based on type, the market is categorized into B-cell lymphomas and T-cell lymphoma. The B-cell lymphomas segment is poised to lead the market with projections to reach a value of USD 9.6 billion by 2032.

• The availability of potential treatments designed to target B-cells specifically such as monoclonal antibodies and chimeric antigen receptor (CAR) T-cell therapies, have demonstrated significant efficacy in managing B-cell Non-Hodgkin lymphoma subtypes. Therefore, by directly targeting cancerous B-cells, these treatments enhance response rates and improve patient outcomes. Thus, owing to such aforementioned advantages associated with B-cells will experience substantial growth over the forecast period.

Learn more about the key segments shaping this market

 Download Free Sample

Based on therapy type, the Non-Hodgkin lymphoma therapeutics market is classified into chemotherapy, targeted therapy, radiation therapy, and other therapy types. The radiation therapy segment accounted for the largest market share of 45.4% in 2023 and is expected to maintain dominance throughout the analysis period.

• The segment's growth is primarily driven by rising initiatives from key market players, including product launches and partnerships. Several companies are executing strategic partnerships to offer the radiopharmaceutical industry unique service solutions for theranostic drug development. For instance, in July 2021, Oncodesign, Covalab, CheMatech, and ABX-CRO partnered to introduce the DRIVE-MRT (molecular radiotherapy) solution. DRIVE-MRT incorporating various technologies related to target validation, vector generation, and optimization, as well as radiochemistry and PET/SPECT imaging techniques. Therefore, significant initiatives such as partnerships and product launches for Non-Hodgkin lymphoma diagnostics are expected to enhance product availability, thereby fostering the market growth.

Based on gender, the Non-Hodgkin lymphoma therapeutics market is segmented into male and female. The male segment accounted for the highest share in the market expected to exhibit CAGR of 7.3% during the analysis period.

• This trend can be attributed to various factors including potentially higher incidence rates among males compared to females. Also, lifestyle factors, genetic predispositions, and environmental exposures may contribute to this disparity.
• Further, the male-dominated landscape emphasizes the need for tailored therapeutic approaches and targeted interventions to address the specific healthcare needs of this demographic.
• Thus, the aforementioned factors driving this gender-based discrepancy are crucial for optimizing treatment strategies and improving outcomes in the Non-Hodgkin lymphoma patient population.

Looking for region specific data?

 Download Free Sample

The U.S. dominated the North American Non-Hodgkin lymphoma therapeutics market accounting for USD 3.9 billion in 2023 and is anticipated to show significant growth over the analysis period.

• The country benefits from advanced healthcare infrastructure, a robust research and development environment, and substantial investments in cancer therapies coupled with the high incidence rate of Non-Hodgkin lymphoma. For instance, according to the American Cancer Society in January 2023, approximately 80,550 people (44,880 males and 35,670 females) were diagnosed with Non-Hodgkin lymphoma.
• Similarly, a study published in the Oncology Journal in December 2022, highlighted the efficacy of radiation therapy such as involved-field radiotherapy, in treating both extranodal and nodal Non-Hodgkin lymphoma.
• Thus, high incidence of Non-Hodgkin lymphoma coupled with availability different therapy types is expected to drive the treatment adoption, thereby augmenting the U.S. market growth.

Germany exhibited a high growth potential in the European Non-Hodgkin lymphoma therapeutics market.

• Germany’s strong position is attributed to several factors including advanced healthcare infrastructure, a robust pharmaceutical industry, and a high prevalence of Non-Hodgkin lymphoma cases.
• According to the data from the Lymphoma Coalition Europe, around 18,320 individuals in Germany received a diagnosis of Non-Hodgkin lymphoma in 2020. The increased number of cases is expected to boost the demand for effective therapeutics, further solidifying the country's prominence in the European market.
• Additionally, the country's research and development initiatives, along with a focus on precision medicine contribute to Germany's leadership in the market.

The Asia Pacific Non-Hodgkin lymphoma therapeutics market is poised for rapid growth with a CAGR of 7.9% during the forecast period.

• The immunotherapeutic approaches including monoclonal antibodies and Chimeric Antigen Receptor T-cell (CAR-T) therapies are integral to Non-Hodgkin lymphoma treatment, showing improved response rates and durable remissions, especially in relapsed or refractory cases.
• Similarly, the market is evolving with ongoing research to enhance the efficacy and expand the applicability of immunotherapies, along with the development and optimization of CAR-T therapies.
• Thus, aforementioned factors along with rising awareness, and growing investments in research are driving the demand for effective therapies in the Asia Pacific region, thereby supplementing the market growth.

Non-Hodgkin Lymphoma Therapeutics Market Share

The market features leading companies providing a wide array of treatment choices. The players are actively engaged in advancing targeted therapies, immunotherapies, and chemotherapy for Non-Hodgkin lymphoma. The market's growth is propelled by ongoing innovations in therapy development and the investigation of combined treatments to enhance patient results and address resistance mechanisms in treating Non-Hodgkin lymphoma.

Non-Hodgkin Lymphoma Therapeutics Market Companies

Few of the prominent players operating in the Non-Hodgkin lymphoma therapeutics industry include

• Astellas Pharma US, Inc
• AstraZeneca PLC
• Bayer AG
• Bristol Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• GSK plc
• F. Hoffmann La-Roche Ltd.
• Janssen Pharmaceuticals Inc.
• Seagen Inc
• Takeda Pharmaceutical Company Ltd.
• Teva Pharmaceutical Industries Ltd.

Non-Hodgkin Lymphoma Therapeutics Industry News

• In May 2024, Bristol Myers Squibb received the U.S. Food and Drug Administration (FDA) approval for Breyanzi, a CD19-directed CAR T cell therapy, for adults with relapsed or refractory follicular lymphoma after two or more systemic therapies. This approval is expected to introduce a new treatment option for lymphoma and enhance their product offerings.
• In May 2023, Genmab A/S and AbbVie obtained approval from the U.S. FDA for Epkinly, designed to treat adults with diffuse large B-cell lymphoma (DLBCL) who have not responded or relapsed after two prior therapies. This approval aimed to support the treatment for capabilities in combating blood cancer, thereby strengthening their business portfolio.

The Non-Hodgkin lymphoma therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments

Click here to Buy Section of this Report

Market, By Type

• B-cell lymphomas    
  • Diffuse large B-cell lymphoma (DLBCL)
  • Follicular lymphoma
  • Mantle cell lymphoma
  • Other B-cell lymphomas
• T-cell lymphoma      
  • Peripheral T-cell lymphoma
  • Cutaneous T-cell lymphoma
  • Anaplastic large cell lymphoma
  • Other T-cell lymphomas

Market, By Therapy Type

• Chemotherapy
• Targeted therapy
• Radiation therapy
• Other therapy types

Market, By Gender

• Male
• Female

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa